Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SI-B001 plus irinotecan in recurrent or metastatic esophageal squamous cell carcinoma
CTR20212601Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Dec 2021
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab, irinotecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Biokin Pharmaceutical. Started Dec 2021; status: active.
02
Drugs
izalontamabirinotecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20212601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212601.